TWiV 713: COVID-19 clinical update #47 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Novavax vaccine phase 3 results (Novavax)
- J&J vaccine phase 3 results (J&J)
- COVID-19 and transmission in K-12 schools (MMWR)
- Lilly mAb therapy (NEJM)
- Regeneron mAb prophylaxis (Regeneron)
- Colchicine for COVID-19 (Cardiol Today)
- Letters read on TWiV 713
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology